6CM
PDSB icon

683 Capital Management’s PDS Biotechnology PDSB Stock Holding History

683 Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-19,280
Closed -$254K – 322
2022
Q4 		$254K Buy
+19,280
New +$136K 0.02% 139
2021
Q3 		– Sell
-25,000
Closed -$314K – 220
2021
Q2 		$314K Buy
+25,000
New +$195K 0.01% 171

Other funds holding PDSB

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
EWA
EP Wealth Advisors Torrance, California $20.3B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

683 Capital Management's PDSB Position: Q1 2023 in Review

683 Capital Management sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 19,280 shares — an estimated $254K sold.

683 Capital Management first reported a position in PDSB in Q2 2021 and held it in 2 quarters. The position peaked at $314K in Q2 2021. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

  • 683 Capital Management reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 19,280 PDS Biotechnology shares in Q1 2023, an estimated $254K.
  • 683 Capital Management first reported a position in PDS Biotechnology in Q2 2021 and held it in 2 quarters.
  • 683 Capital Management's PDS Biotechnology position peaked at $314K in Q2 2021.
  • 68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.